Oliver Stoeltzing

Summary

Country: Germany

Publications

  1. ncbi Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor
    Oliver Stoeltzing
    Departments of Surgery and Surgical Oncology, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, 93042, Regensburg, Germany
    Langenbecks Arch Surg 395:185-92. 2010
  2. ncbi Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
    Sven A Lang
    Departments of Surgery and Surgical Oncology, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, Regensburg, Germany
    Mol Cancer Ther 7:3509-18. 2008
  3. ncbi Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition
    Christina Hackl
    Department of Surgery, University of Regensburg Medical Center, Franz Josef Straus Allee 11, 93042 Regensburg, Germany
    BMC Cancer 10:668. 2010
  4. ncbi Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells
    Sven A Lang
    Department of Surgery, University Medical Center Regensburg, Regensburg, Germany
    Biochim Biophys Acta 1803:435-42. 2010
  5. ncbi Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis
    Christian Moser
    Departments of Surgery and Surgical Oncology, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, 93042 Regensburg, Germany
    Eur J Cancer 44:1577-86. 2008
  6. ncbi Effect of heat-shock protein-90 (HSP90) inhibition on human hepatocytes and on liver regeneration in experimental models
    Christina Hackl
    Department of Surgery, University of Regensburg Medical Center, Regensburg, Germany
    Surgery 147:704-12. 2010
  7. ncbi ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo
    Christian Moser
    Department of Surgery, Regensburg Medical Center, Regensburg, Germany
    BMC Cancer 8:206. 2008
  8. ncbi Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice
    Sven A Lang
    Departments of Surgery and Surgical Oncology, University of Regensburg Medical Center, Regensburg, Germany
    Hepatology 49:523-32. 2009
  9. ncbi Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo
    Christian Moser
    Department of Surgery, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, 93042 Regensburg, Germany
    Mol Cancer Ther 6:2868-78. 2007
  10. ncbi Up-regulation of Krüppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha
    Akira Mori
    Department of Surgery and Surgical Oncology, University of Regensburg Medical Center, Regensburg, Germany
    Mol Cancer Res 7:1390-8. 2009

Collaborators

Detail Information

Publications14

  1. ncbi Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor
    Oliver Stoeltzing
    Departments of Surgery and Surgical Oncology, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, 93042, Regensburg, Germany
    Langenbecks Arch Surg 395:185-92. 2010
    ..We proposed that (90)Y-DOTATOC could be used in a neoadjuvant intention for improving therapy of hepatic NET metastases...
  2. ncbi Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
    Sven A Lang
    Departments of Surgery and Surgical Oncology, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, Regensburg, Germany
    Mol Cancer Ther 7:3509-18. 2008
    ..Dual targeting of Raf and VEGFR2 appears to be a valid strategy for therapy of pancreatic cancer...
  3. ncbi Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition
    Christina Hackl
    Department of Surgery, University of Regensburg Medical Center, Franz Josef Straus Allee 11, 93042 Regensburg, Germany
    BMC Cancer 10:668. 2010
    ..Here we followed-up on our previous observation that inhibition of Hsp90 may increase ATF3 expression and sought to determine the role of ATF3 in colon cancer...
  4. ncbi Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells
    Sven A Lang
    Department of Surgery, University Medical Center Regensburg, Regensburg, Germany
    Biochim Biophys Acta 1803:435-42. 2010
    ..In conclusion, inhibition of mTORC2 may abrogate unfavorable signaling effects of mTOR inhibitors, hence providing a novel rationale for therapy...
  5. ncbi Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis
    Christian Moser
    Departments of Surgery and Surgical Oncology, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, 93042 Regensburg, Germany
    Eur J Cancer 44:1577-86. 2008
    ..In conclusion, the IGF-IR inhibitor NVP-AEW541 effectively disrupts IGF-I signalling and reduces pancreatic tumour growth. Hence, blocking IGF-IR could prove valuable for targeted therapy of pancreatic cancer...
  6. ncbi Effect of heat-shock protein-90 (HSP90) inhibition on human hepatocytes and on liver regeneration in experimental models
    Christina Hackl
    Department of Surgery, University of Regensburg Medical Center, Regensburg, Germany
    Surgery 147:704-12. 2010
    ..In this study, we investigated the impact of HSP90 inhibition on liver regeneration in murine models...
  7. ncbi ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo
    Christian Moser
    Department of Surgery, Regensburg Medical Center, Regensburg, Germany
    BMC Cancer 8:206. 2008
    ..We hypothesized that therapeutic inhibition of HIF-1alpha could be achieved by using a novel tubulin-binding agent (ENMD-1198). ENMD-1198 is an analog of 2-methoxyestradiol (2ME2) with antiproliferative and antiangiogenic activity...
  8. ncbi Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice
    Sven A Lang
    Departments of Surgery and Surgical Oncology, University of Regensburg Medical Center, Regensburg, Germany
    Hepatology 49:523-32. 2009
    ..Hence, the concept of targeting tumor cells, ECs, and VSMCs by blocking Hsp90/mTOR could prove valuable for treatment of HCC...
  9. ncbi Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo
    Christian Moser
    Department of Surgery, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, 93042 Regensburg, Germany
    Mol Cancer Ther 6:2868-78. 2007
    ..Hence, targeting Hsp90 could prove valuable for treatment of advanced colorectal cancer by effectively inhibiting colon cancer growth and hepatic metastasis and improving the efficacy of oxaliplatin...
  10. ncbi Up-regulation of Krüppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha
    Akira Mori
    Department of Surgery and Surgical Oncology, University of Regensburg Medical Center, Regensburg, Germany
    Mol Cancer Res 7:1390-8. 2009
    ..In conclusion, overexpression of KLF5 in human pancreatic cancer cells is not mediated by KRAS/Raf/MAPK/Erk signaling, but involves the IL-1beta/IL-1R system, p38, and the transcription factor HIF-1alpha...
  11. ncbi Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer
    Johannes Taeger
    Department of Surgery, University of Regensburg Medical Center, Franz Josef Strauss Allee 11, 93042 Regensburg, Germany
    Mol Cancer Ther 10:2157-67. 2011
    ..These data provide evidence that targeting FGFR/PDFGR/VEGFR with TKI258 may be effective in human pancreatic cancer and warrants further clinical evaluation...
  12. ncbi Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model
    Sven Arke Lang
    Department of Surgery, University of Regensburg Medical Center, Regensburg, Germany
    Langenbecks Arch Surg 393:333-41. 2008
    ..We hypothesized that concomitant inhibition of Raf and vascular endothelial growth factor receptor 2 (VEGFR2) will affect tumor growth and angiogenesis of HCC...
  13. ncbi Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer
    Christian Moser
    Department of Surgery, University of Regensburg Medical Center, 93042 Regensburg, Germany
    Anticancer Res 29:2031-42. 2009
    ..Against this background, the following review focuses on the current preclinical experience and value of targeting Hsp90 for the therapy of gastrointestinal carcinomas...
  14. ncbi Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotop
    Sven A Lang
    Department of Surgery, University of Regensburg Medical Center, Regensburg, Germany
    Clin Cancer Res 13:6459-68. 2007
    ....